|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Microfluidizer Á¾ÇÕÄ«´Ù·Î±× |
Phone |
|
|
  ´ëÇ¥ÀüÈ |
1577-7956   |
  º»     »ç |
031-457-9187   |
  ´ë     Àü |
042-932-1265 |
|
|
Web Site Visitors |
|
|
  Today |
608     |
  Yesterday |
685     |
  Since 2006 |
1,880,549     |
|
|
|
|
¿µÁøÄÚÆÛ·¹ÀÌ¼Ç Á¾ÇÕÄ«´Ù·Î±× |
|
|
2020³â ¹Ì±¹ HDT Bio (Host Directed Therapeutics Biotechnology) »ç´Â °·ÂÇÑ RNA Delivery Ç÷§ÆûÀÎ
LION¢â (Lipid Iron Oxide Nanoparticles) RNA Delivery System À» °³¹ßÇÏ¿´½À´Ï´Ù.
LION¢â RNA Delivery System Àº ´ÙÀ½ ³»¿ëÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.
Squalene : |
Vaccine Adjuvant ±â´ÉÀ» Çϸç LION¢â ÀÇ °ñ°ÝÀ» Çü¼ºÇÏ´Â ¿ªÇÒ |
SPIO : |
Super paramagnetic Iron Oxide, Fe3O4, ¾çÀ̿»êÈö : ¾çÀÌ¿ÂÀ» ¶ç°í ÀÖ¾î RNA ¿Í °áÇÕÇÏ´Â ±â´É |
DOTAP : |
the cationic lipid 1,2-dioleoyl-3-trimethylammonium propane : RNA ¿Í °áÇÕÇÏ¿© RNA-combined LION¢â À»
¸Å¿ì stable »óÅ·ΠÀ¯Áö½ÃÄÑ ÁÖ´Â ÇÙ½ÉÀûÀÎ ±â´É |
SPAN 60 : |
°è¸éÈ°¼ºÁ¦ |
Tween 80 : |
°è¸éÈ°¼ºÁ¦ |
LION¢â system À» RNA ¿Í mixing Çϸé RNA °¡ LION¢â ¿¡ °ÇÏ°Ô °áÇÕÇÏ¿© RNA-combined LION ÀÌ µÈ´Ù.
RNA-combined LION¢â ÀÇ RNA °¡ ¾î´À Á¤µµ ¾ÈÁ¤ÇÏ°Ô Á¸ÀçÇÏ´ÂÁö È®ÀÎÇϱâ À§ÇØ RNAse ó¸®ÇÏ¿© Àü±â¿µµ¿À¸·Î È®ÀÎÇÑ °á°ú
LION¢â ¿¡ combined µÈ RNA ´Â ¸Å¿ì ¾ÈÁ¤ÇÑ »óŸ¦ À¯ÁöÇÏ´Â °ÍÀ» ¾Ë ¼ö ÀÖ¾ú´Ù.
¶ÇÇÑ LION¢â ¿¡ combine µÈ RNA ´Â ¿Âµµº¯È¿¡µµ ¸Å¿ì ¾ÈÁ¤ÇÑ »óŸ¦ À¯ÁöÇÏ°í ÀÖ´Â °ÍÀ» È®ÀÎÇÒ ¼ö ÀÖ¾ú´Ù.
LION¢â formulation
LION¢â formulation that SPIO nanoparticles within a hydrophobic squalene core to enhance formulation stability.
- 37.5 mg/ml squalene
- 30 mg/ml DOTAP chloride
- 37 mg/ml Span¢ç 60
- 37 mg/ml Tween¢ç 80
LION¢â formulation °úÁ¤
1 |
combine the iron oxide nanoparticles with the oil phase (Squalene, Span 60, and DOTAP) |
|
2 |
sonicate for 30 minutes in a 65¡ÆC water bath |
|
3 |
Separately, the aqueous phase, containing Tween 80 in water, was prepared with
continuous stirring until all components were dissolved. |
|
4 |
The oil and aqueous phases were then mixed and emulsified using mixer |
|
5 |
the crude colloid was subsequently processed by passaging through a microfluidizer
at 20,000 psi with a LM10 microfluidizer equipped with a H10Z-100 ¥ìm ceramic
interaction chamber (Microfluidics) until the z-average hydrodynamic diameter
- reached 50 ¡¾5 nm with a 0.2 polydispersity index. |
|
6 |
The microfluidized LION¢â was terminally filtered with a 200 nm pore-size polyethersulfone
(PES) filter and stored at 2-8¡ÆC |
|
7 |
Replicon RNA was complexed with LION¢â formulations and placed on ice for 30 min |
|
LION¢â RNA Delivery Platform Ư¡
- |
¸Å¿ì ¸¹Àº ¾çÀÇ target ´Ü¹éÁúÀ» »ý¼ºÇÏ¿© ºü¸¥ ¸é¿ª ¶Ç´Â Ä¡·á ÀÛ¿ëÀ» ±â´ë (~50¹è) |
|
- |
ÀÎü³»¿¡¼ ¸Å¿ì ¾ÈÁ¤ÇÏ´Ù, |
|
- |
¸é¿ªº¸°Á¦ (vaccine adjuvant) °¡ Æ÷ÇԵǾî ÀÖ´Ù. |
|
- |
»ó¿Â º¸°üÀÌ °¡´É |
|
- |
°¡°ÝÀÌ Àú·Å |
|
- |
Á¦Á¶°¡ ¸Å¿ìÆí¸®ÇÏ´Ù |
|
LION¢â RNA Delivery System À» ÀÌ¿ëÇÏ¿© COVID-19 mRNA Vaccine À» ¸¸µå´Â °úÁ¤Àº HDT Bio »çÀÇ Chief Scientific Officier ÀÎ Dr. Darrick Carter °¡ ÁøÇàÇÏ´Â ¾Æ·¡ ¼¼¹Ì³ª µ¿¿µ»óÀ» ÂüÁ¶ÇϽʽÿä.
±×¸®°í LION¢â RNA Delivery System °ü·Ã ÀÚ¼¼ÇÑ ³»¿ëÀº ´ÙÀ½ »çÀÌÆ®¸¦ ÂüÁ¶ÇϽʽÿä.
- bioRxiv
|
¡Ø ÀÌ È¸éÀ» click ÇϽøé Youtube µ¿¿µ»óÀ¸·Î À̵¿µË´Ï´Ù. |
ÀÌ ¹ßÇ¥´Â ´ÙÀ½°ú °°Àº ³»¿ëÀ¸·Î ÀÌ·ç¾î Á® ÀÖ½À´Ï´Ù.
- Overview of RNA from discovery to approval of an mRNA vaccine in 2020
- LNPs, CNEs and LION¢â - The limitations and advantages of major delivery systems   in use for RNA
- How self-amplifying RNAs work
- Vaccine results with LION¢â, a next generation RNA delivery system
- Future uses of mRNA Technology for medical breakthroughs
- Cost consideration for scale-up
- Using Microfluidizer¢ç processors in manufacturing for global commercial distribution |
|
|
|